These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25891739)

  • 1. Nodular hyperplasia of the gastrointestinal tract after liver transplantation: role of immunosuppressive therapy? A case report.
    Ennaifer R; Ben Slama S; Romdhane H; Bayar R; Cheikh M; Ben Nejma H; Mestiri H; Bel Hadj N
    Transplant Proc; 2015 Apr; 47(3):820-2. PubMed ID: 25891739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.
    Bunnapradist S; Lentine KL; Burroughs TE; Pinsky BW; Hardinger KL; Brennan DC; Schnitzler MA
    Transplantation; 2006 Jul; 82(1):102-7. PubMed ID: 16861948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil in liver transplantation.
    McDiarmid SV
    Clin Transplant; 1996 Feb; 10(1 Pt 2):140-5. PubMed ID: 8680052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Klupp J; Glanemann M; Junge G; Pfitzmann R; Bahra M; Radtke C; Neumann U; Neuhaus R; Neuhaus P
    Clin Transplant; 2006; 20(3):272-83. PubMed ID: 16824141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
    Boillot O; Seket B; Dumortier J; Pittau G; Boucaud C; Bouffard Y; Scoazec JY
    Liver Transpl; 2009 Nov; 15(11):1426-34. PubMed ID: 19877264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nodular lymphoid hyperplasia of the duodenum in cancers of the gastrointestinal tract].
    Tessmann D; Mau C; Nagel KH
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):266-9. PubMed ID: 6525969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.
    Kamar N; Oufroukhi L; Faure P; Ribes D; Cointault O; Lavayssiere L; Nogier MB; Esposito L; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Oct; 20(10):2231-6. PubMed ID: 16046517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil-induced colitis with graft versus host disease-like features in a liver transplant recipient.
    Patra S; Vij M; Sukanya B; Kapoor D
    Indian J Pathol Microbiol; 2012; 55(4):506-8. PubMed ID: 23455789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation.
    Reggiani P; Arru M; Regazzi M; Gatti S; Molinaro MD; Caccamo L; Maggi U; Melada E; Paone G; Rossi G
    Transplant Proc; 2005 May; 37(4):1697-9. PubMed ID: 15919435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
    Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications.
    Barrera-Pulido L; Alamo-Martínez JM; Marín-Gómez LM; Suárez-Artacho G; Bernal-Bellido C; Domínguez-Usero D; Tallón-Aguilar L; Pareja-Ciuró F; Sousa-Martín JM; García-González I; Gómez-Bravo MA
    Transplant Proc; 2009; 41(6):2192-4. PubMed ID: 19715870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
    Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
    Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
    Lopez-Solis R; DeVera M; Steel J; Fedorek S; Sturdevant M; Hughes C; Humar A
    Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
    Doria C; Ramirez CB; Frank AM; Vaccino S; Fraser N; Marino IR
    Clin Transplant; 2009; 23(6):882-6. PubMed ID: 19573090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.